Business Wire

1. Arcadia Receives $4.5M Grant From USAID To Develop Salt-Tolerant Rice And Gather Greenhouse Gas Emissions Data From Nitrogen Efficient Crops
   1/31/2012
   Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, recentlyy announced that it has been awarded a 5-year, $4.5M grant from the U.S. Agency for International Development (USAID) to develop salt-tolerant rice and measure greenhouse gas emissions from conventional rice fields in Bangladesh and Nitrogen Use Efficient (NUE) crops in Indonesia.
2. BioSante Pharmaceuticals Provides Corporate Update
   1/31/2012
   BioSante Pharmaceuticals, Inc. recently announced a corporate update.
3. Bionest And PMC Address Optimization Of Personalized Medicine Strategies
   1/31/2012
   Bionest Partners, a premier strategy and management consulting firm for life science industries, and a recognized leader in personalized medicine strategy consulting, announces the publication of an article in a supplement to the Dec. 23, 2011 issue of Science.
4. BioLineRx Signs Exclusive License Agreement For BL-8020, An Oral Treatment For Hepatitis C
   1/24/2012
   BioLineRx, a biopharmaceutical development company, announced recently it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. BL-8020 has been developed for anti-viral therapy by Professor Philippe Halfon, Co-Founder and President of Genoscience.
5. Genzyme Announces FDA Approval Of Framingham Manufacturing Plant
   1/24/2012
   Genzyme, a Sanofi company, announced recently that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme (agalsidase beta). This follows the previously announced approval by the European Medicines Agency (EMA) last week.
6. Selventa Granted Patent For Discovery Of Biomarker Profiles
   1/23/2012
   Selventa, a biomarker discovery company that enables personalized healthcare through stratification of patients based on disease-driving mechanisms, recently announced that the U.S. Patent & Trademark Office has issued the Company U.S. Patent No 8,802,109, titled "Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems."
7. Precision BioSciences Announces That The US Patent Office Rejects All Claims To Cellectis Patent
   1/23/2012
   Precision BioSciences, Inc., a leader in the field of genome engineering, recently announced that the United States Patent and Trademark Office (PTO) has issued a first, non-final Office Action in the reexamination proceedings for U.S. Pat. No. 7,897,372 ("the ‘372 patent") that is owned by Cellectis SA. Importantly, this Office Action rejected every claim of the ‘372 patent as being anticipated by or obvious in view of prior art.
8. FDA Updates TYSABRI (Natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor
   1/20/2012
   Recently Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS).
9. BIO Thanks USDA, Congratulates Fiberight And Partners On Forward Progress In Commercializing Advanced Biofuels
   1/20/2012
   Private companies continue to make progress in building advanced biofuel biorefineries. The Biotechnology Industry Organization (BIO) recently congratulates Fiberight and its technology partner Novozymes, a member of BIO, on their progress.
10. Medgenics' Receives Allowance For Key European Patent
    1/20/2012
    Medgenics, Inc, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, recently announced that the Company received notice of ‘Intention to Grant' from the European Patent Office for the patent application entitled "USE OF DERMAL MICRO ORGANS," with allowed claims covering a core element of its Biopump protein therapy technology.

First 1 2 3 4 5 6 7 8 9 10 10 (Last)